Sign in
CC

Chris Coetzee

Managing Director at Baird Financial Group, Inc.

Chicago, IL, US

Chris Coetzee is a Managing Director at Baird, leveraging over three decades of investment banking experience to deliver financing and advisory services across a wide range of sectors. Joining Baird in 1994, he has played a pivotal role in transactions for numerous middle-market companies, guiding clients through mergers, acquisitions, and capital-raising initiatives. Throughout his distinguished career, Chris has become recognized for his expertise in deal execution and client service, contributing to Baird's reputation as a leading platform for institutional equities and investment banking. He maintains strong professional credentials reflecting his extensive background in the industry.

Chris Coetzee's questions to Axsome Therapeutics (AXSM) leadership

Question · Q1 2025

Chris, on behalf of Joel Beatty from Baird, asked about Axsome's plans for the recent SYMBRAVO data in CGRP non-responders, specifically if it would be pursued as a new indication or label expansion. He also inquired about the status of pursuing a label expansion for SYMBRAVO in adolescents.

Answer

Ari Maizel, CCO, explained that while the CGRP data is compelling for clinicians, the company is not currently seeking to add it to the label as a new indication but will communicate the data through medical affairs and compliant promotional activities. Mark Jacobson, COO, confirmed that the pediatric development work for SYMBRAVO is underway as agreed with the FDA.

Ask follow-up questions

Fintool

Fintool can predict Axsome Therapeutics logo AXSM's earnings beat/miss a week before the call

Let Fintool AI Agent track Chris Coetzee for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free